IL264395A - Macrocycle kinase inhibitors - Google Patents

Macrocycle kinase inhibitors

Info

Publication number
IL264395A
IL264395A IL264395A IL26439519A IL264395A IL 264395 A IL264395 A IL 264395A IL 264395 A IL264395 A IL 264395A IL 26439519 A IL26439519 A IL 26439519A IL 264395 A IL264395 A IL 264395A
Authority
IL
Israel
Prior art keywords
macrocycle
kinase inhibitors
kinase
inhibitors
macrocycle kinase
Prior art date
Application number
IL264395A
Other languages
English (en)
Hebrew (he)
Original Assignee
Tp Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tp Therapeutics Inc filed Critical Tp Therapeutics Inc
Publication of IL264395A publication Critical patent/IL264395A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
IL264395A 2016-07-28 2019-01-22 Macrocycle kinase inhibitors IL264395A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662367886P 2016-07-28 2016-07-28
PCT/US2017/044214 WO2018022911A1 (en) 2016-07-28 2017-07-27 Macrocycle kinase inhibitors

Publications (1)

Publication Number Publication Date
IL264395A true IL264395A (en) 2019-02-28

Family

ID=61016718

Family Applications (1)

Application Number Title Priority Date Filing Date
IL264395A IL264395A (en) 2016-07-28 2019-01-22 Macrocycle kinase inhibitors

Country Status (15)

Country Link
US (1) US10689400B2 (OSRAM)
EP (1) EP3490564A4 (OSRAM)
JP (1) JP2019527230A (OSRAM)
KR (1) KR20190034225A (OSRAM)
CN (1) CN109715165A (OSRAM)
AU (1) AU2017302019A1 (OSRAM)
BR (1) BR112019001607A2 (OSRAM)
CA (1) CA3031100A1 (OSRAM)
IL (1) IL264395A (OSRAM)
MX (1) MX2019001125A (OSRAM)
RU (1) RU2019105587A (OSRAM)
SG (1) SG11201900163PA (OSRAM)
TW (1) TW201815799A (OSRAM)
WO (1) WO2018022911A1 (OSRAM)
ZA (1) ZA201901034B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3636649T (lt) 2014-01-24 2024-04-10 Turning Point Therapeutics, Inc. Diarilo makrociklai kaip proteinkinazių moduliatoriai
US10316044B2 (en) 2015-07-02 2019-06-11 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
ES2818528T3 (es) 2015-07-21 2021-04-13 Turning Point Therapeutics Inc Macrociclo de diarilo quiral y uso del mismo en el tratamiento del cáncer
EP3490564A4 (en) 2016-07-28 2020-02-26 Turning Point Therapeutics, Inc. MACRO CYCLE Kinase Inhibitors
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
EP3658148B1 (en) 2017-07-28 2024-07-10 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
CN109516999B (zh) * 2017-11-01 2021-08-17 郑州泰基鸿诺医药股份有限公司 用作蛋白质激酶调节剂的化合物及其应用
MX2020006490A (es) 2017-12-19 2020-08-17 Turning Point Therapeutics Inc Compuestos macrociclicos para tratar enfermedades.
CN111971287B (zh) 2018-03-28 2023-06-02 重庆复尚源创医药技术有限公司 作为trk激酶抑制剂的大环化合物
PL3786167T3 (pl) 2018-04-25 2024-11-25 Primegene (Beijing) Co., Ltd. Diarylowy związek makrocykliczny i kompozycja farmaceutyczna oraz ich zastosowanie
CA3224945C (en) 2018-07-31 2025-11-18 Loxo Oncology, Inc. SPRAY DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPAN-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
FI3870579T3 (fi) 2018-10-22 2025-01-02 Alumis Inc Tyk2-inhibiittoreita ja niiden käyttöjä
BR112021019070A2 (pt) * 2019-03-26 2022-02-15 Ventyx Biosciences Inc Ligantes de pseudoquinase tyk2
US12410191B2 (en) 2019-05-21 2025-09-09 Zhejiang Hisun Pharmaceutical Co., Ltd. Macrolide derivatives, preparation method and application thereof
CN112110938B (zh) * 2019-06-21 2021-11-09 成都海博为药业有限公司 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途
WO2021027503A1 (zh) * 2019-08-12 2021-02-18 罗欣药业(上海)有限公司 三环类化合物、其制备方法、中间体及应用
KR20220088699A (ko) 2019-09-27 2022-06-28 디스크 메디슨, 인크. 골수섬유증 및 관련 상태의 치료 방법
EP4114530A4 (en) * 2020-03-02 2024-04-17 Turning Point Therapeutics, Inc. Therapeutic uses of macrocyclic compounds
JP2023528223A (ja) 2020-05-13 2023-07-04 ディスク・メディシン・インコーポレイテッド 骨髄線維症を処置するための抗ヘモジュベリン(hjv)抗体
WO2021244609A1 (zh) * 2020-06-04 2021-12-09 成都倍特药业股份有限公司 具有大环结构的化合物及其用途
CN116829562B (zh) * 2021-02-10 2025-04-01 深圳国顺康医药科技有限公司 一种巨环化合物、药物组合物以及其用途
CN113354548A (zh) * 2021-04-12 2021-09-07 常熟耐素生物材料科技有限公司 一种基于六亚甲基四胺的植物多烯酚醛胺环氧固化剂及其制备方法
WO2023078267A1 (zh) * 2021-11-02 2023-05-11 赛诺哈勃药业(成都)有限公司 作为蛋白激酶调节剂的含氨基大环化合物
WO2023208244A1 (zh) * 2022-04-29 2023-11-02 南京明德新药研发有限公司 大环类化合物及其应用
WO2025010294A2 (en) * 2023-07-03 2025-01-09 Blossomhill Therapeutics, Inc. Macrocyclic compounds and use as tyk2 inhibitors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE195935T1 (de) 1993-03-25 2000-09-15 Upjohn Co Formyl- oder cyano- substituierte indolderivate mit dopaminergischer wirkung
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
CN102143750B (zh) * 2008-09-08 2014-04-02 默克专利有限公司 用作蛋白激酶抑制剂的大环嘧啶
US8450322B2 (en) 2008-09-22 2013-05-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors
TR201807039T4 (tr) 2008-10-22 2018-06-21 Array Biopharma Inc Trk kinaz inhibitörleri olarak sübstitüe edilmiş pirazolo[1,5-]pirimidin bileşikleri.
JP5769199B2 (ja) 2008-10-31 2015-08-26 ジェネンテック, インコーポレイテッド ピラゾロピリミジンjak阻害剤化合物と方法
ES2628418T3 (es) 2010-05-20 2017-08-02 Array Biopharma, Inc. Compuestos macrocíclicos como inhibidores de la TRK cinasa
US8757434B2 (en) * 2010-07-01 2014-06-24 The Coca-Cola Company Merchandiser
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
PT2710018T (pt) * 2011-05-19 2022-03-01 Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio Compostos macrocíclicos como inibidores de proteína quinases
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
KR20140053330A (ko) 2011-08-19 2014-05-07 머크 샤프 앤드 돔 코포레이션 마크로락탐의 제조를 위한 방법 및 중간체
JP6046728B2 (ja) 2011-09-30 2016-12-21 オンコデザイン エス.ア. 大環状flt3キナーゼ阻害剤
BR112014007654A8 (pt) * 2011-09-30 2018-06-12 Ipsen Pharma Inibidores de lrrk2 quinase macrocíclicos.
PT2822953T (pt) 2012-03-06 2017-04-06 Pfizer Derivados macrocíclicos para o tratamento de doenças proliferativas
CA2866164C (en) 2012-03-09 2020-07-07 Lexicon Pharmaceuticals, Inc. Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
IN2014DN07384A (OSRAM) 2012-03-09 2015-04-24 Lexicon Pharmaceuticals Inc
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
WO2014140299A1 (en) * 2013-03-15 2014-09-18 Oncodesign S.A Macrocyclic rip2 kinase inhibitors
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
LT3636649T (lt) 2014-01-24 2024-04-10 Turning Point Therapeutics, Inc. Diarilo makrociklai kaip proteinkinazių moduliatoriai
US10316044B2 (en) 2015-07-02 2019-06-11 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
SMT202400213T1 (it) 2015-07-06 2024-07-09 Turning Point Therapeutics Inc Polimorfo di diaril macrociclo
ES2818528T3 (es) 2015-07-21 2021-04-13 Turning Point Therapeutics Inc Macrociclo de diarilo quiral y uso del mismo en el tratamiento del cáncer
EP3490564A4 (en) 2016-07-28 2020-02-26 Turning Point Therapeutics, Inc. MACRO CYCLE Kinase Inhibitors
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
EP3658148B1 (en) 2017-07-28 2024-07-10 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof

Also Published As

Publication number Publication date
BR112019001607A2 (pt) 2019-04-30
EP3490564A1 (en) 2019-06-05
TW201815799A (zh) 2018-05-01
KR20190034225A (ko) 2019-04-01
US10689400B2 (en) 2020-06-23
CN109715165A (zh) 2019-05-03
US20190169208A1 (en) 2019-06-06
SG11201900163PA (en) 2019-02-27
WO2018022911A1 (en) 2018-02-01
ZA201901034B (en) 2021-06-30
MX2019001125A (es) 2019-06-12
RU2019105587A (ru) 2020-08-28
JP2019527230A (ja) 2019-09-26
CA3031100A1 (en) 2018-02-01
EP3490564A4 (en) 2020-02-26
AU2017302019A1 (en) 2019-02-07
RU2019105587A3 (OSRAM) 2020-11-18

Similar Documents

Publication Publication Date Title
ZA201901034B (en) Macrocycle kinase inhibitors
IL268614A (en) Aminotriazolopyridines as kinase inhibitors
ZA201808431B (en) Pyrazolopyrimidine derivatives as kinase inhibitor
EP3131900A4 (en) Heterocyclic kinase inhibitors
PL3305788T3 (pl) Inhibitor kinazy janusowej
IL274207A (en) Aminoimidazopyridazines as kinase inhibitors
IL255750A (en) Heterocyclic compounds as kinase inhibitors
GB201615282D0 (en) Tankyrase inhibitors
ZA201701841B (en) Macrocyclic lrrk2 kinase inhibitors
PL3359543T3 (pl) Pochodne kukurbiturylu
IL266789A (en) Heterocyclic compounds as kinase inhibitors
IL265139B (en) Dopamine-b-hydroxylase inhibitors
GB201612860D0 (en) Inhibitors
ZA201808238B (en) Certain protein kinase inhibitors
ZA201701331B (en) Macrocyclic rip2 kinase inhibitors
HK40009742A (en) Macrocycle kinase inhibitors
GB201404570D0 (en) Macrocyclic kinase inhibitors
GB201404555D0 (en) Macrocyclic kinase inhibitors
HK40004305A (en) Kinase inhibitors
GB201614783D0 (en) Kinases inhibitors
GB201519382D0 (en) Kinase inhibitors
GB201519381D0 (en) Kinase inhibitors
GB201613945D0 (en) Compounds useful as kinase inhibitors